A study published in Cell Metabolism (2024) investigates the cardiometabolic characteristics of individuals with metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). The study compared 20 adults with MHO (normal fasting glucose and triglyceride, oral glucose tolerance, intrahepatic triglyceride content, and whole-body insulin sensitivity), 20 adults with MUO (prediabetes, hepatic steatosis, and whole-body insulin resistance), and 15 metabolically healthy lean individuals. The findings revealed that individuals with MHO had altered skeletal muscle biology (decreased ceramide content and increased expression of genes involved in BCAA catabolism and mitochondrial structure/function), altered adipose tissue biology (decreased expression of genes involved in inflammation and extracellular matrix remodeling, and increased expression of genes involved in lipogenesis), lower 24-h plasma glucose, insulin, non-esterified fatty acids and triglycerides, higher plasma adiponectin and lower plasma PAI-1 concentrations, and decreased oxidative stress. These findings suggest potential mechanisms responsible for MHO and the metabolic heterogeneity of obesity. The study also found that individuals with MHO had greater beta-cell function, higher whole-body, muscle and liver insulin sensitivity, and lower rates of hepatic de novo lipogenesis and cholesterol synthesis compared to those with MUO. Additionally, individuals with MHO had greater plasma adiponectin concentration, lower oxidative stress, lower skeletal muscle ceramide content, and greater expression of genes involved in BCAA catabolism and mitochondrial structure and oxidative function. These results provide a comprehensive physiological atlas of the differences in cardiometabolic outcomes between individuals with MHO and MUO and identify differences in adipose tissue and skeletal muscle biology that could be involved in the pathogenesis of the metabolic abnormalities associated with obesity. The study also found that individuals with MHO had greater beta-cell function and higher whole-body, muscle and liver insulin sensitivity compared to those with MUO. The study highlights the heterogeneity in the cardiometabolic abnormalities associated with obesity and suggests that some individuals with obesity are resistant to the adverse metabolic effects of excess body fat. The study also found that individuals with MHO had greater plasma adiponectin concentration, lower oxidative stress, lower skeletal muscle ceramide content, and greater expression of genes involved in BCAA catabolism and mitochondrial structure and oxidative function. These findings suggest that differences in adipose tissue and skeletal muscle biology may help preserve metabolic health in response to obesity. The study also found that individuals with MHO had greater beta-cell function and higher whole-body, muscle and liver insulin sensitivity compared to those with MUO. The study highlights the heterogeneity in the cardiometabolic abnormalities associated with obesity and suggests that some individuals with obesity are resistant to the adverse metabolic effects of excess body fat.A study published in Cell Metabolism (2024) investigates the cardiometabolic characteristics of individuals with metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). The study compared 20 adults with MHO (normal fasting glucose and triglyceride, oral glucose tolerance, intrahepatic triglyceride content, and whole-body insulin sensitivity), 20 adults with MUO (prediabetes, hepatic steatosis, and whole-body insulin resistance), and 15 metabolically healthy lean individuals. The findings revealed that individuals with MHO had altered skeletal muscle biology (decreased ceramide content and increased expression of genes involved in BCAA catabolism and mitochondrial structure/function), altered adipose tissue biology (decreased expression of genes involved in inflammation and extracellular matrix remodeling, and increased expression of genes involved in lipogenesis), lower 24-h plasma glucose, insulin, non-esterified fatty acids and triglycerides, higher plasma adiponectin and lower plasma PAI-1 concentrations, and decreased oxidative stress. These findings suggest potential mechanisms responsible for MHO and the metabolic heterogeneity of obesity. The study also found that individuals with MHO had greater beta-cell function, higher whole-body, muscle and liver insulin sensitivity, and lower rates of hepatic de novo lipogenesis and cholesterol synthesis compared to those with MUO. Additionally, individuals with MHO had greater plasma adiponectin concentration, lower oxidative stress, lower skeletal muscle ceramide content, and greater expression of genes involved in BCAA catabolism and mitochondrial structure and oxidative function. These results provide a comprehensive physiological atlas of the differences in cardiometabolic outcomes between individuals with MHO and MUO and identify differences in adipose tissue and skeletal muscle biology that could be involved in the pathogenesis of the metabolic abnormalities associated with obesity. The study also found that individuals with MHO had greater beta-cell function and higher whole-body, muscle and liver insulin sensitivity compared to those with MUO. The study highlights the heterogeneity in the cardiometabolic abnormalities associated with obesity and suggests that some individuals with obesity are resistant to the adverse metabolic effects of excess body fat. The study also found that individuals with MHO had greater plasma adiponectin concentration, lower oxidative stress, lower skeletal muscle ceramide content, and greater expression of genes involved in BCAA catabolism and mitochondrial structure and oxidative function. These findings suggest that differences in adipose tissue and skeletal muscle biology may help preserve metabolic health in response to obesity. The study also found that individuals with MHO had greater beta-cell function and higher whole-body, muscle and liver insulin sensitivity compared to those with MUO. The study highlights the heterogeneity in the cardiometabolic abnormalities associated with obesity and suggests that some individuals with obesity are resistant to the adverse metabolic effects of excess body fat.